EXEL vs TGTX
Exelixis vs TG Therapeutics, Inc. — AI-powered side-by-side comparison
VS
TGTX
TG Therapeutics, Inc.
60
Watch
| Metric | EXEL | TGTX |
|---|
| AI Score |
67
|
60
|
| Price |
$51.30
|
$49.86
|
| P/E Ratio |
15.60×
|
16.39×
|
| ROE |
36.2%
|
69.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
82.4%
|
| Debt / Equity |
0.09×
|
1.25×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.0
|
42.0
|
| Beta |
0.422
|
1.666
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus TGTX.
EXEL leads by 7 points.
EXEL scores 67/100 (Buy) versus TGTX at 60/100 (Watch).
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
TGTX Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 76.1% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 22.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 72.3% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- EPS growing 633.7% YoY — Growth
Bear Case
- Price-to-book of 21.1x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 22.5% signals elevated volatility — Risk